|
|
|
|
|
by Symmetry
2754 days ago
|
|
Normally competition means companies can make as many of a product as they want in order to gain market share from each other. FDA regulated drugs often operate on a production quota system where a given company is only allowed to manufacture a pre-approved amount. If the FDA decreased the EpiPen quota by the same amount that the generic was allowed to be produced in then you might not expect to see any reduction in price. Of course they might have just left EpiPen's quota the same, the article doesn't have that sort of information and it might not be publicly available. |
|
My understanding is that this only applies to Schedule I and II drugs.
The Epipen, along with most other pharmaceutical drugs, do not fall under those categories.